Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34747
Title: Unified framework for patient-derived, tumor-organoid-based predictive testing of standard-of-care therapies in metastatic colorectal cancer.
Austin Authors: Tan, Tao;Mouradov, Dmitri;Lee, Margaret;Gard, Grace;Hirokawa, Yumiko;Li, Shan;Lin, Cong;Li, Fuqiang;Luo, Huijuan;Wu, Kui;Palmieri, Michelle;Leong, Evelyn;Clarke, Jordan;Sakthianandeswaren, Anuratha;Brasier, Helen;Tie, Jeanne;Tebbutt, Niall C ;Jalali, Azim;Wong, Rachel;Burgess, Antony W;Gibbs, Peter;Sieber, Oliver M
Affiliation: Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC 3052, Australia.
HIM-BGI Omics Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, BGI Research, Hangzhou 310000, China; Guangdong Provincial Key Laboratory of Human Disease Genomics, Shenzhen Key Laboratory of Genomics, BGI Research, Shenzhen 518083, China.
Medical Oncology
Issue Date: 19-Dec-2023
Publication information: Cell Reports. Medicine 2023-12-19; 4(12)
Abstract: Predictive drug testing of patient-derived tumor organoids (PDTOs) holds promise for personalizing treatment of metastatic colorectal cancer (mCRC), but prospective data are limited to chemotherapy regimens with conflicting results. We describe a unified framework for PDTO-based predictive testing across standard-of-care chemotherapy and biologic and targeted therapy options. In an Australian community cohort, PDTO predictions based on treatment-naive patients (n = 56) and response rates from first-line mCRC clinical trials achieve 83% accuracy for forecasting responses in patients receiving palliative treatments (18 patients, 29 treatments). Similar assay accuracy is achieved in a prospective study of third-line or later mCRC treatment, AGITG FORECAST-1 (n = 30 patients). "Resistant" predictions are associated with inferior progression-free survival; misclassification rates are similar by regimen. Liver metastases are the optimal site for sampling, with testing achievable within 7 weeks for 68.8% cases. Our findings indicate that PDTO drug panel testing can provide predictive information for multifarious standard-of-care therapies for mCRC.
URI: https://ahro.austin.org.au/austinjspui/handle/1/34747
DOI: 10.1016/j.xcrm.2023.101335
ORCID: 
Journal: Cell Reports. Medicine
Start page: 101335
PubMed URL: 38118423
ISSN: 2666-3791
Type: Journal Article
Subjects: colorectal cancer
patient-derived tumor organoid
precision medicine
predictive drug testing
Colorectal Neoplasms/diagnosis
Colorectal Neoplasms/drug therapy
Colonic Neoplasms/drug therapy
Antineoplastic Agents/therapeutic use
Appears in Collections:Journal articles

Show full item record

Page view(s)

20
checked on Jul 15, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.